Head-To-Head Contrast: Bolt Biotherapeutics (NASDAQ:BOLT) & Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Insider & Institutional Ownership

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 30.9% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Abbott Laboratories and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.99%	20.18%	10.84%
Bolt Biotherapeutics	-665.56%	-69.46%	-48.55%

Analyst Recommendations

This is a breakdown of current ratings for Abbott Laboratories and Bolt Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0	4	11	0	2.73
Bolt Biotherapeutics	0	5	0	0	2.00

Abbott Laboratories currently has a consensus price target of $131.57, suggesting a potential upside of 15.97%. Bolt Biotherapeutics has a consensus price target of $3.50, suggesting a potential upside of 582.79%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Abbott Laboratories.

Risk and Volatility

Abbott Laboratories has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.

Earnings & Valuation

This table compares Abbott Laboratories and Bolt Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$40.11 billion	4.91	$5.72 billion	$3.29	34.48
Bolt Biotherapeutics	$7.88 million	2.49	-$69.20 million	($1.71)	-0.30

Abbott Laboratories has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Abbott Laboratories beats Bolt Biotherapeutics on 10 of the 14 factors compared between the two stocks.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.